TY  - CHAP
AU  - Kamil Musilek
AU  - Marketa Komloova
AU  - Ondrej Holas
AU  - Anna Horova
AU  - Jana Zdarova-Karasova
AU  - Kamil Kuca
ED  - Joseph A. Pruitt
Y1  - 2012-01-20
PY  - 2012
T1  - Myasthenia Gravis – Current Treatment Standards and Emerging Drugs
N2  - Myasthenia gravis is presently an incurable antibody-mediated autoimmune disorder characterized by generalized voluntary skeletal muscle weakness. The cause of the weakness is a defect at the neuromuscular junction level, in which autoimmune antibodies block the receptors responsible for initiating muscular contraction. Literally translated from its Latin and Greek etymological roots, myasthenia gravis means "grave muscle weakness". Fortunately, advances in modern medicine have resulted in a reduction of the truly "grave" outcomes for those inflicted but, without a cure, the gravity surrounding the disease remains
BT  - A Look into Myasthenia Gravis
SP  - Ch. 3
UR  - https://doi.org/10.5772/31127
DO  - 10.5772/31127
SN  - 
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-26
ER  -